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A family of five neutral cyclometalated iridium(III) tetrazolato complexes and their methylated 
cationic analogues have been synthesised and characterised. The complexes are distinguished by 
variations of the substituents or degree of π conjugation on either the phenylpyridine or tetrazolato 
ligands. The photophysical properties of these species have been evaluated in organic and aqueous 
media, revealing predominantly a solvatochromic emission originating from mixed metal-to-ligand 
and ligand-to-ligand charge transfer excited states of triplet multiplicity. These emissions are 
characterised by typically long excited state lifetimes, with values around hundreds of nanoseconds, 
and quantum yields around 5-10% in aqueous media. Methylation of the complexes caused a 
systematic red-shift of the emission profiles. Changes in the chemical structure of the neutral 
cyclometalated iridium(III) tetrazolato species resulted in complexes that imaged the endoplasmic 
reticulum and lipid droplets. On the other hand, the majority of the cationic complexes interacted 
with mitochondria. The amount of complexes found within cells varied considerably, even between 
complexes showing similar values of lipophilicity, which potentially suggests diverse mechanisms 
of entrance. Methylation of the complexes evidenced more pronounced cytotoxicity with respect to 




Luminescent metal complexes of transition [e.g. Ru(II), Re(I), Ir(III), Au(I), and Pt(II)][1-4] and 
lanthanoid elements [e.g. Eu(III) and Tb(III) for visible emission; Yb(III) for near-infrared 
emission][5,6] have specific photophysical properties that are ideal for cellular imaging. These 
properties have the potential to solve some of the critical drawbacks associated with more 
traditionally investigated organic fluorophores.[7] Appropriately designed metal complexes exhibit 
enhanced photostability, and therefore do not suffer from rapid photobleaching, thus allowing 
imaging on longer time scales.[1] Luminescent heavy metal complexes are also typically 
characterised by large Stokes shifts, which prevents concentration quenching phenomena.[1] 
Furthermore, their relatively longer excited state lifetimes make this class of luminophores 
amenable to time-gated imaging to improve signal-to-noise ratio by minimising interference from 
fast decaying autofluorescence.[8]  
Luminescent cyclometalated iridium(III) complexes are proving to be exceptional systems for the 
development of markers for live cell imaging.[9,10] The chemical, photophysical, and biological 
targeting properties of these complexes can be readily varied by altering the coordinating ligands or 
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by chemical coupling.[11,12] In addition, their absorption and emission profiles can be modulated 
along the spectral range of visible light from blue to red, and further into the near-infrared region, 
by introducing appropriate functional groups or by the variation of the π conjugation on the 
aromatic ligands.[13,14] Following similar principles, the lipophilicity of these complexes can be 
adjusted to favour transport across the cellular membrane, while maintaining adequate solubility in 
aqueous media.[1,15] A large number of luminescent iridium complexes have been reported to 
possess not only the capacity to internalise into cells,[13,16] but also the ability to accumulate within 
specific organelles such as mitochondria,[17-22] lysosomes,[15,23-25] nuclei,[26-30] and endoplasmic 
reticulum.[31-34] Some iridium complexes have been conjugated with biologically relevant moieties 
such as carbohydrates,[18,35] biotin/avidin,[36-39] amino acids,[23] and proteins[40], in an attempt to 
impart and control their biospecificity. Furthermore, examples of complexes with the ability to 
sense targeted biological species via reversible or irreversible modulation of their photophysical 
properties have also been reported.[21,27,34,41-47] 
A rationalisation of the structure-activity relationship (SAR) of luminescent iridium complexes is 
still difficult to achieve from the current knowledge base. This is partly due to the fact that labelling 
experiments are often carried out with a diverse range of complexes using different cell lines or 
model systems. Moreover, the staining protocols used are often variable when comparing data from 
different research groups.[48] In addition, a priority has been given to producing cationic iridium 
complexes, seemingly arising from the fact that they might possess increased solubility in aqueous 
media and exhibit more favourable membrane transport by exploiting membrane potential 
gradients. However, many of these molecular complexes have exhibited moderate to acute 
cytotoxicity, a property that can be regarded favourably for the joint development of 
therapeutics,[22,24,49-51] but which is not ideal for visualising cellular functions in live cell systems. 
Notably, only a handful of neutral iridium complexes have been investigated as cellular imaging 
agents.[15,23,25,47,52,53] 
We previously showed that neutral luminescent rhenium(I) complexes can be used for live cell 
imaging, offering different biospecificity to the more popularly investigated cationic rhenium 
complexes.[54] For example, we demonstrated unprecedented staining of polar lipids in live cells 
using the complex fac-[Re(CO)3(phen)L] (L = 5-(4-cyanophenyl)tetrazolate; phen = 1,10-
phenanthroline).[55,56] Furthermore, simple chemical modulation of the tetrazolato ancillary ligand 
has been a viable strategy to impart alternative biological behaviour, with successful staining of the 
endoplasmic reticulum and the visualisation of membrane events in live cells.[57] We have now 
focused our attention on the investigation of cyclometalated iridium complexes bound to tetrazolato 
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ligands, which is a family of neutral and analogous cationic iridium species that have not been 
previously used as molecular probes for live cell imaging. For this scope, we prepared an initial 
library of complexes by modifying the functional groups on the ligands and by the extension of the 
π conjugation (Figure 1). Due to the intrinsic reactivity of the coordinated tetrazolato ligand 
towards electrophiles,[11,58,59] these neutral complexes could also be easily methylated, allowing the 
preparation of the analogous cationic species. This approach allowed the preparation of a family of 
complexes for a more systematic SAR investigation that can relate how variations in the chemical 
structure and charge might influence the biological behaviour of the iridium markers in relation to 
cellular incubation, localisation, and cytotoxicity.  
 
 
Figure 1. Neutral and cationic iridium tetrazolato complexes synthesised and investigated for live 
cell imaging. 
 
Results and Discussion 
 
Synthesis of the tetrazolato ligands and corresponding iridium complexes 
The adopted synthetic procedures are shown in Figure 2. The ligand precursor 2,5-dicyanopyridine 
was obtained in three steps starting from commercially available 2,5-pyridinedicarboxylic acid. 
Following a Fisher esterification to form the corresponding methyl ester groups, aminolysis with 
aqueous ammonia gave the corresponding primary amides. Lastly, dehydration of the amide groups 
































































































dicyanopyridine was reacted with sodium azide in the presence of zinc bromide in water at reflux, 
yielding the HTzPyCN ligand. Complete separation of HTzPyCN from the ditetrazole byproduct 
(present in 5-10% molar amount determined by NMR analysis) by selective protonation was 
challenging, and the impure HTzPyCN was used as recovered for complexation with iridium. The 








































































R = H [Ir(ppy)2(TzPyCN)]







































































R = H; X = CN [Ir(ppy)2(MeTzPyCN)]+
R = F; X = CN [Ir Ir(F2ppy)2(MeTzPyCN)]+


























To prepare the family of neutral iridium complexes [Ir(ppy)2(TzPyCN)], [Ir(F2ppy)2(TzPyCN)], 
[Ir(ppy)2(TzQn)], and [Ir(ppy)2(TziQn)], the corresponding chloro-bridged iridium dimers 
(bearing either ppy or F2ppy as cyclometalating ligands) were reacted with a slight excess of the 
corresponding pyridyl or (iso)quinolyl tetrazolato species.[11] The complex [Ir(ppy)2(TzPyPhCN)] 
was prepared via a different route, involving a Suzuki coupling of the previously reported 
[Ir(ppy)2(TzPyBr)][11] with 4-cyanophenylboronic acid. Previous attempts to react the iridium 
chloro-bridged dimer with the pre-formed corresponding tetrazolato ligand were unsuccessful, as an 
inseparable mixture of products was obtained. Methylation of all the neutral complexes was 
performed by treatment with methyl trifluoromethanesulphonate, followed by metathesis with 
ammonium hexafluorophosphate.[11] All the synthesised complexes were characterised by means of 
NMR (see SI for all the 1H and 13C spectra) and IR spectroscopy as well as elemental analysis. 
 
X-ray Structural Determination 
Single crystals suitable for X-ray diffraction were obtained for the neutral [Ir(F2ppy)2(TzPyCN)] 
and the charged [Ir(ppy)2(MeTzPyPhCN)][PF6] complexes. These species crystallized in the 
monoclinic I2/a and P2/n space groups, respectively (Figure 3). The coordination arrangement of 
the ligands is analogous, with the two pyridine rings of the phenylpyridine ligands adopting a trans 
configuration, while the two cyclometalated phenyl rings being arranged in cis configuration. The 
rest of the coordination sphere is occupied by the two nitrogen atoms of the tetrazole and pyridine 
rings. The [Ir(ppy)2(MeTzPyPhCN)][PF6] complex highlights methylation of the tetrazole ring at 
the N3 position. 
 
 
Figure 3. X-ray crystal structures of [Ir(F2ppy)2(TzPyCN)] (left) and [Ir(ppy)2(MeTzPyPhCN)]+ 
(right), with displacement ellipsoids drawn at the 50% probability level. Lattice solvent molecules 
and counter anion (PF6-) are omitted for clarity. 
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Photophysical Properties 
A summary of the photophysical properties for the synthesised iridium complexes, measured from 
dichloromethane and aqueous (ca 10-5 M) solutions are listed in Table 1 (see SI for photophysical 
data in PBS, lysosomal pH fluid solution, and ethyl laurate). The aqueous media contained about 
0.2% DMSO to favour the solubilisation of the iridium complexes. The various solvents have been 
chosen to identify potential modulations of the photophysical properties of the iridium complexes in 
diverse cellular environments such as cytoplasm, endosomes, acidic organelles (e.g. lysosomes), 
and lipid-rich compartments like membranes, endoplasmic reticulum, and lipid droplets. The 
photophysical properties were measured in air-equilibrated solutions to account for the presence of 
oxygen in live cells. However, to confirm triplet multiplicity of the excited states, the measurements 
were also performed in degassed dichloromethane solutions.[62] 
The absorption spectra from air-equilibrated dichloromethane solutions are presented in Figure 4 
(for the spectral profiles in other solvents see SI). All the iridium complexes show intense 
absorption bands in the UV region (250–300 nm), which are associated with ligand-centred (LC) π-
π* transitions, followed by bands of lower intensity tailing off into the visible region of the spectra. 
These lower energy bands are ascribed to spin allowed (singlet to singlet) and spin forbidden 





Table 1. Photophysical data of the iridium complexes from 10-5 M dichloromethane and aqueous 
solutions. 
 
















H2Oa 253 (3.52), 377 (0.69) 618 











H2Oa 256 (4.83), 302 (3.36), 366 (1.16) 552 











H2Oa 286 (1.87), 350 (0.86), 421 (0.34) 580 






CH2Cl2 266 (8.93), 376 (1.44) 680 
31 (79), 168 (21) 
35 (61), 362 (39) 
0.012 
0.014 












H2Oa 260 (4.12), 309 (1.55), 353 (0.66) 636 











H2Oa 264 (3.82), 390 (0.35) 605 










H2Oa 266 (4.41), 350 (2.35), 425 (0.97) 600 










H2Oa 268 (3.42), 350 (2.00), 435 (0.80) 590 











H2Oa 251 (8.30), 307 (2.52), 364 (1.09) 630 











H2Oa 251 (6.64), 291 (2.60), 355 (1.36) 660 




a Aqueous solutions contain 0.2% DMSO. b For the biexponential excited state lifetime (τ), the relative weights of the exponential 
curves are reported in parentheses; τdeaer is reported only for dichloromethane solutions. c Measured versus [Ru(bpy)3]2+ in H2O 





































Figure 4. Absorption spectra of the iridium complexes from 10-5 M air-equilibrated 
dichloromethane solutions. 
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Excitation of the iridium complexes at 375 nm results in long-lived orange to red emission in air-
equilibrated dichloromethane solutions, and the emission spectra measured at 298 K are shown in 
Figure 5 (for the emission spectra in other solvents see SI). The neutral complexes 
[Ir(ppy)2(TzPyCN)], [Ir(F2ppy)2(TzPyCN)], and [Ir(ppy)2(TzPyPhCN)] are characterised by 
broad and featureless emission bands, that are typical for radiative decays from excited states of 
charge transfer character.[12] The [Ir(ppy)2(TzPyCN)] complex presents a red-shifted maximum at 
618 nm, which is ascribed to a stabilisation of the unoccupied π* orbitals localised on the TzPyCN- 
ligand caused by the electron-withdrawing nature of the nitrile functional group.[11] As expected, the 
addition of electron-withdrawing fluoride substituents on the ppy ligands causes a blue-shift of the 
emission maximum for [Ir(F2ppy)2(TzPyCN)] (λem = 542 nm), as a consequence of the stabilisation 
of the occupied π orbitals of the ligands and iridium 5d orbitals composing the mixed 
LLCT(F2ppy→TzPyCN) and MLCT(Ir→TzPyCN) transition.[11] The emission maximum of 
[Ir(ppy)2(TzPyPhCN)] at 560 nm is again blue-shifted with respect to [Ir(ppy)2(TzPyCN)], albeit 
to a lesser extent when compared to [Ir(F2ppy)2(TzPyCN)]. This trend is ascribed to the fact that 
the electron-withdrawing effect of the nitrile group on the pyridyltetrazole π* system is decreased 
by the addition of a phenyl ring spacer. The emission profiles of the methylated complexes 
[Ir(ppy)2(MeTzPyCN)]+ (λem = 680 nm), [Ir(F2ppy)2(MeTzPyCN)]+ (λem = 600 nm), and 
[Ir(ppy)2(MeTzPyPhCN)]+ (λem = 600 nm) are red-shifted compared to their corresponding neutral 
complexes. Once more, this red-shift demonstrates that the π* system of the pyridyl tetrazole ligand 
acts as an electron acceptor in the charge transfer transitions.[11,63] When comparing the emission 
maxima of these three methylated iridium complexes, the trend for the emission properties is 
analogous to that observed for their neutral counterparts, with the most red-shifted emission 
originating from [Ir(ppy)2(MeTzPyCN)]+. 
The iridium complexes containing quinoline and isoquinoline-functionalised tetrazolato ligands, 
[Ir(ppy)2(TzQn)] and [Ir(ppy)2(TziQn)], reveal emission bands that are similarly ranging between 
500 and 750 nm (Figure 5). Compared to the previously published complex [Ir(ppy)2(TzPy)],[11] 
where TzPy- is 5-(2’-pyridyl)tetrazolate, displaying a structured emission band with peaks at 481 
and 510 nm, the complexes [Ir(ppy)2(TzQn)] and [Ir(ppy)2(TziQn)] present a red-shifted emission 
that is rationalised by the increased π conjugation on passing from a phenyl to a quinolyl or 
isoquinolyl substituent. The structures of these two bands appear to be quite different. The emission 
profile of [Ir(ppy)2(TzQn)] is broad and structureless, whereas that of [Ir(ppy)2(TziQn)] appears to 
be structured with a vibronic progression spaced around 1,300 cm-1. Furthermore, the excited state 
lifetime of [Ir(ppy)2(TziQn)] is significantly longer than that of [Ir(ppy)2(TzQn)] (Table 1). These 
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results suggest the presence of a more dominating charge transfer character for the emission of 
[Ir(ppy)2(TzQn)].[64] On the other hand, the excited state of [Ir(ppy)2(TziQn)] seems to be strongly 
influenced by LC character.[64] To confirm this assumption, we performed time dependent density 
functional theory (TD-DFT) analysis on [Ir(ppy)2(TzQn)] and [Ir(ppy)2(TziQn)] (see SI). The 
results show that the lower energy bands are mainly composed of MLCT and LLCT transitions. 
However, in the case of [Ir(ppy)2(TziQn)], there is also a contribution from the HOMO-4→LUMO 
transition corresponding to a LC transition localised on the TziQn- ligand. A further indication of 
the LC character of the excited state of [Ir(ppy)2(TziQn)] comes from the significantly elongated 
excited state decay lifetime in degassed dichloromethane, reaching a value of 6.713 µs.[65] 
As expected, the emission profiles of the methylated [Ir(ppy)2(MeTzQn)]+ and 
[Ir(ppy)2(MeTziQn)]+ complexes appear red-shifted, broad, and structureless (Figure 5).  
For all the complexes, an elongation of the excited state lifetime decay (τ) and increase of 
photoluminescence quantum yield (Φ) values is observed upon degassing. This behaviour is 
indicative of the triplet spin multiplicity of the excited state.[12,62] 
The analysis of the emission bands in various solvents reveals solvatochromic behaviour, with a 
red-shift of the emission maxima upon increasing the polarity of the solvent. The most blue-shifted 
emission is recorded in ethyl laurate, while the emission red-shifts by ~20-30 nm in 
dichloromethane, with the exception of [Ir(ppy)2(MeTzPyPhCN)]+ and [Ir(ppy)2(MeTziQn)]+ for 
which almost no shift is observed. The emission bands further shift (~10-30 nm) towards longer 
wavelength in aqueous media. There are no significant differences in the various aqueous solvents, 
apart from [Ir(ppy)2(MeTzPyPhCN)]+ that shows a 22 nm red-shift on passing from PBS to a 
lysosomal pH fluid solution. The methylated complex [Ir(ppy)2(MeTzPyCN)]+ is found to have 
appreciable emission only in dichloromethane solution, as the complex is virtually non-emissive in 
aqueous solvents. In general, the methylated complexes highlight a greater degree of quenching in 
aqueous solvents with respect to their neutral analogues. While conclusive explanations cannot be 
drawn from these data, potential causes could be ascribed to increased non-radiative decays due to 
energy gap law and the higher solubility of the cationic complexes in aqueous solvents. In fact, we 
previously observed a similar behavior for neutral rhenium complexes, where a decrease of 





Figure 5. Emission spectra of the iridium complexes from ca 10-5 M air-equilibrated 
dichloromethane solutions with excitation at 375 nm. 
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Lipophilicity and cellular incubation 
The lipophilicity of the iridium complexes was measured by the shake-flask method using a pH = 
7.4 buffered PBS solution and n-octanol.[66] The calculated logD7.4 values are listed in Table 2. The 
values obtained are within a range that is similar to those reported previously for cyclometalated 
iridium complexes,[18,24,26,53] and, in the case of the neutral complexes, fluorophores for the lipid 
droplets of the BODIPY family (functionalised 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene 
cores).[67] The values for the five neutral complexes are comprised between 2.01 and 2.68. 
Methylation of the iridium complexes lowers the lipophilicity, which is ascribed to the introduction 
of the cationic charge, and results in logD7.4 values in the range 1.49-1.97. The lowest lipophilicity 
is observed for the complex [Ir(ppy)2(MeTzPyCN)]+ at 0.64. A comparison of the logD7.4 values 
between [Ir(ppy)2(TzPyCN)], [Ir(ppy)2(TzPyPhCN)], [Ir(ppy)2(TzQn)], and [Ir(ppy)2(TziQn)], 
shows that extending the conjugation of the tetrazolato ligands increases lipophilicity. A similar 
trend also holds true for the methylated analogues, [Ir(ppy)2(MeTzPyCN)]+, 
[Ir(ppy)2(MeTzPyPhCN)]+, [Ir(ppy)2(MeTzQn)]+, and [Ir(ppy)2(MeTziQn)]+. The introduction of 
fluoride substituents on aromatic moieties is often associated with an increase in logD7.4 values. [68-
71] However, this trend was only observed in the methylated complexes, where logD7.4 increased 
from 0.64 for [Ir(ppy)2(MeTzPyCN)]+ to 1.86 for [Ir(F2ppy)2(MeTzPyCN)]+. In contrast, little 
change was observed in the logD7.4 value between [Ir(ppy)2(TzPyCN)] and [Ir(F2ppy)2(TzPyCN)], 
consistently with previously published cyclometalated iridium complexes with lipophilicity values 
around 2.[24]  
 
Table 2. Distribution coefficient values (logD7.4) for neutral and methylated iridium complexes. 
Complex logD7.4 




[Ir(ppy)2(TzPyCN)] 2.09 ± 0.06 0.042 ± 0.004 21.16 ± 1.85 
[Ir(F2ppy)2(TzPyCN)] 2.01 ± 0.05 0.319 ± 0.049 159.71 ± 46.95 
[Ir(ppy)2(TzPyPhCN)] 2.68 ± 0.08 0.171 ± 0.042 85.46 ± 20.76 
[Ir(ppy)2(MeTzPyCN)]+ 0.64 ± 0.03 0.015 ± 0.002 7.35 ± 0.81 
[Ir(F2ppy)2(MeTzPyCN)]+ 1.86 ± 0.02 0.025 ± 0.007 12.74 ± 3.26 
[Ir(ppy)2(MeTzPyPhCN)]+ 1.87 ± 0.08 0.045 ± 0.005 22.74 ± 2.48 
[Ir(ppy)2(TzQn)] 2.23 ± 0.04 0.346 ± 0.070 173.03 ± 35.20 
[Ir(ppy)2(TziQn)] 2.57 ± 0.05 0.063 ± 0.011 31.61 ± 5.60 
[Ir(ppy)2(MeTzQn)]+ 1.68 ± 0.05 0.372 ± 0.038 186.24 ± 18.92 
[Ir(ppy)2(MeTziQn)]+ 1.49 ± 0.06 0.515 ± 0.085 257.29 ± 42.64 
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a Average number of moles of iridium complex incubated within a H9c2 cell (see Experimental 
Section for incubation conditions). b The relative concentration was calculated assuming an average 
volume of H9c2 cell equal to 2 pL. 
Cellular uptake and localisation 
The cellular uptake for the synthesised iridium complexes was studied by means of ICP-MS 
measurements, and the results are reported in Table 2. The H9c2 cells were incubated with 
complexes at 20 µM in cell culture medium (0.2% DMSO) for 30 minutes at 37 °C. The calculated 
cellular concentration values were obtained assuming an average volume of a single H9c2 cell 
equal to 2 pL.[72] An analysis of the data reveals that the association between internalisation and 
lipophilicity does not follow a simple trend. For example, three of the neutral complexes, 
[Ir(F2ppy)2(TzPyCN)], [Ir(ppy)2(TzPyPhCN)], and [Ir(ppy)2(TzQn)] exhibit high iridium 
intracellular concentrations indicating good cellular internalisation. The remaining two complexes, 
[Ir(ppy)2(TzPyCN)] and [Ir(ppy)2(TziQn)], exhibit lower intracellular iridium concentrations 
although their lipophilicity fell within the range of the aforementioned neutral complexes. On the 
other hand, only the cationic iridium complexes bound to the quinolyl and isoquinolyl tetrazolato 
ligands exhibit efficient cellular internalisation. The lack of straightforward trends suggests that the 
mechanism of internalisation might be different for the various complexes.  
The cellular localisation of the iridium complexes was investigated via confocal microscopy. 
Following the same incubation protocol described for the ICP-MS measurements, complexes could 
be detected in cells by single photon excitation at 403 nm and were also shown to be compatible 
with two-photon imaging modalities, with optimal excitation in the range of 810-830 nm (see SI). 
All the complexes could be readily detected within cells in an emission interval of 525-644 nm, 
(consistent with emissions recorded in the cuvette), allow for co-staining with commercially 
available organelle markers. The [Ir(ppy)2(MeTzPyCN)]+ complexes was the only exception which 
had low detectability within the instrument range (420-740 nm) constant with measures taken in 
aqueous media, thus was omitted from co-localisation studies.  
All the neutral complexes had similar staining patterns and evidenced a diffuse network emanating 
from the nucleus and extending into the cytoplasm (Figure 6), consistent with the endoplasmic 
reticulum (ER). In addition, the methylated cationic complex [Ir(ppy)2(MeTzQn)]+ also detected 
this reticular network in the perinuclear region (Figure 6). Co-staining with ER-Tracker™ revealed 
relatively high Pearson’s correlation coefficients,[73] with values above 0.7, confirming these 




Figure 6. Iridium complexes interacting with endoplasmic reticulum (ER) in live H9c2 cells. 
Micrographs of H9c2 cells stained with the iridium complexes (green) and counter-stained with ER 
Tracker™ (red). Yellow/orange colour in the merge indicates marker colocalisation. The iridium 
complexes were excited at 403 nm and the emission was collected in the region 525-644 nm; ER-
Tracker was excited at 561 nm and the emission was collected in the region 570-620 nm. Scale bars 
= 10 µm. 
 
While the neutral complexes and the methylated cationic complex [Ir(ppy)2(MeTzQn)]+  were 
predominately localised within the ER, their emission was also detected within compartments in the 
cytoplasm that were not labelled with ER-Tracker™. The morphology and localisation of these 
compartments resembled lipid droplets. BODIPY® 500/510 C1,C12, a fatty acid analogue that 
localises with lipid droplets and partially with the endoplasmic reticulum, produced strong co-
	 16	
localisation with these complexes (Figure 7). A high Pearson’s correlation coefficients was obtained 
for these complexes and BODIPY® 500/510 C1,C12 (ranging between 0.63 and 0.92; see SI),[73] 




Figure 7. Iridium complexes localise with lipid droplets in live H9c2 cells. Micrographs of H9c2 
cells stained with the iridium complexes (green) and counter-stained with BODIPY® 500/510 
C1,C12 fatty acid analogue (red). Yellow/orange colour in the merge indicates marker colocalisation. 
The iridium complexes were excited at 403 nm and the emission was collected in the region 525-
644 nm; BODIPY500/510 was excited at 488 nm and the emission was collected in the region 500-
550 nm. Scale bars: 10 µm. 
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The methylated complexes [Ir(F2ppy)2(MeTzPyCN)]+ and [Ir(ppy)2(MeTzPyPhCN)]+ localised to 
elongated structures throughout the cytoplasm, a staining pattern that is characteristics of 
mitochondrial association (Figure 8). Co-staining with MitoTracker® Red CMXRos confirmed this 
interaction, with Pearson’s correlation coefficient between 0.65 and 0.71 (see SI).[73] It is possible 
that the positive charge favours the transport of these complexes across the mitochondrial 
membrane as a consequence of the intermembrane electrical potential gradient. This explanation is 
consistent with the typical mitochondrial affinity of delocalised lipophilic cations such as 
phosphonium salts, or previously reported cationic metal complexes.[74] It is interesting to note that 
the complex [Ir(F2ppy)2(MeTzPyCN)]+ also stained what appears to be the ER along with the 
mitochondria, although co-staining between the complex and ER-Tracker could not be performed 
(see SI). While [Ir(ppy)2(MeTziQn)]+ also co-located with MitoTracker® Red CMXRos, this 
charged complex appeared to induce apoptosis, characterised by the formation of cellular vacuoles 
and rounding of the mitochondria (Figure 8). In this case, ER-Tracker™ was also observed to co-
localise with these unusual cellular structures. An increase of caspase activity in H9c2 cells after 
incubation with [Ir(ppy)2(MeTziQn)]+ confirmed the induction of apoptosis (see SI).[75] 
 
 
Figure 8. Iridium complexes interacting with mitochodria in live H9c2 cells. Micrographs of H9c2 
cells stained with the iridium complexes (green) and counter-stained with Mito-Tracker®Red 
CMXRos (red). Yellow/orange colour in the merge indicates colocalisation between markers. The 
iridium complexes were excited at 403 nm and the emission was collected in the region 525-644 
nm; MitoTracker was excited at 561 nm and the emission was collected in the region 570-620 nm. 




Figure 9. Confocal micrographs of H9c2 cells incubated with iridium complexes at 37 °C (A) or 4 
°C (C). Scale bar = 5 µm. (B) Histogram showing the emission intensity of iridium complexes 
detected from H9c2 cells when incubated at 37 °C (grey bars) or 4 °C (black bars) to inhibit energy 
dependent cell entry. 
 
Confocal microscopy was also employed to assess the mechanism of cellular internalisation. The 
intensity of the emission from the iridium complexes was compared between cells incubated at 37 
and 4 °C (Figure 9), the latter to suppress energy-mediated mechanisms of entrance. The emission 
detected from each complex shows a good correlation with the average amount of iridium found in 
cells measured by ICP-MS (Table 2). Cells incubated with [Ir(F2ppy)2(TzPyCN)], 
[Ir(ppy)2(TzPyPhCN)], [Ir(ppy)2(TzQn)], [Ir(ppy)2(MeTzQn)]+ and [Ir(ppy)2(MeTziQn)]+ show 
the highest emission intensity, and also record the largest concentration of iridium per cell. The 
trend in emission intensity also correlates well with the quantum yield values (Table 1). For 
example, the emission detected from [Ir(ppy)2(TzPyPhCN)] is comparable with 
[Ir(ppy)2(MeTzQn)]+ and [Ir(ppy)2(MeTziQn)]+, even though the former was detected at a lower 
concentration. The emission detected from each of the cells following incubation at 4 °C was 
significantly reduced. This suggests that energy dependent pathways are predominantly involved in 
the cellular uptake of these complexes, a result that is consistent with previously studied 
cyclometalated iridium complexes incubated in various cell lines.[17,26,42,46,76] Again, the lack of 
	 19	
clear trends in Figure 9 suggests variable mechanism of entrance even for subtle chemical changes. 
For example, [Ir(ppy)2(TzQn)] is detected well upon incubation at 4 °C, but [Ir(ppy)2(TziQn)] is 
barely visible, even though the two complexes differ only by the orientation of the quinolyl 
substituents and have very similar lipophilicity values. Our results reinforce previously reported 
views[48,77] that conclusions based exclusively on lipophilicity measurements might not be adequate, 
even for families of complexes with very similar chemical structures. 
 
Cytotoxicity 
The cell viability was assessed via MTS assay to highlight cytotoxic effects after internalisation of 
the iridium complexes (without photoexcitation). The H9c2 cells were incubated for either 2 hours 
or 24 hours with the complexes at 20 µM or 40 µM. An important trend emerges from the collected 
results (Figure 10), highlighting the fact that while the neutral complexes only exhibit slight 
cytotoxicity, cell viability is reduced upon incubation with the corresponding cationic complexes. 
On comparing the cytotoxicity and ICP-MS data from incubated cells, it is clear that cytotoxic 
effects are not exclusively dependent on the relative amount of iridium complexes incubated within 
the cells. For example, the fluorinated complex [Ir(F2ppy)2(TzPyCN)] does not exhibit significant 
cytotoxicity compared to its methylated analogue [Ir(F2ppy)2(MeTzPyCN)]+, even though the 
concentration of the latter is lower by an order of magnitude. These results suggest that cytotoxic 
effect for this family of iridium complexes might be strongly related to their relative cellular 
localisation. 
The only exception to the cytotoxic effect of the cationic complexes seems to be related to 
[Ir(ppy)2(MeTzPyCN)]+, which from the ICP-MS results showed minimal accumulation within the 
cells. Unfortunately however, the localisation of this compound could not be assessed due to its 






Figure 10. Cell viability after 2 and 24 hours incubation with the iridium complexes at 20 and 40 
µM. Neutral complexes are represented by blue bars, whereas cationic complexes are represented 
by green bars. 0) Control (0.2% DMSO in serum-free DMEM media); 1) [Ir(ppy)2(TzPyCN)]; 2) 
[Ir(ppy)2(MeTzPyCN)]+; 3) [Ir(F2ppy)2(TzPyCN)]; 4) [Ir(F2ppy)2(MeTzPyCN)]+; 5) 
[Ir(ppy)2(TzPyPhCN)]; 6) [Ir(ppy)2(MeTzPyPhCN)]+; 7) [Ir(ppy)2(TzQn)]; 8) 
[Ir(ppy)2(MeTzQn)]+; 9) [Ir(ppy)2(TziQn)]; 10); and [Ir(ppy)2(MeTziQn)]+. 
 
It is well known that phosphorescent metal complexes act as sensitisers for singlet oxygen.[78] 
Therefore, during imaging with confocal microscopy a resting time of at least 30 seconds is always 
provided to the cells to recover from a potential increase in reactive oxygen species. This is a 
protocol we optimised during our previous studies using rhenium complexes as cellular labels.[79] 
Using this protocol, and imaging cells incubated for 30 minutes with a 20 µM solution of iridium 
complex, blebbing of the cell membrane was never observed. On the other hand, cells incubated 
under the same conditions and continuously illuminated showed signs of blebbing within a 30 
minute timeframe (see SI).  These results demonstrate that the neutral series of iridium tetrazolato 
complexes possess very promising properties for the development of iridium-based markers for 
imaging of the ER in live cells. This is in contrast to other cationic iridium complexes that were 
previously shown to accumulate in the endoplasmic reticulum, but which were cytotoxic due to the 




Photobleaching experiments were carried out on H9c2 cells incubated with the iridium complexes 
at 20 µM for 30 minutes (see SI). The cells were illuminated continuously at 403 nm for 900 s, and 
the decrease in emission intensity was compared with that from cells incubated with ER-Tracker. 
All the complexes evaluated in cells showed better photostability than ER-Tracker, with the 
cationic complexes exhibiting emission intensity above 85% of the initial values after 900 s 
irradiation. The neutral iridium complexes proved to be slightly more prone to photobleaching, but 
still displayed emission above 70% of the initial emission intensity after 900 s irradiation. The only 
exception was the fluorinated [Ir(F2ppy)(TzPyCN)], which showed a photobleaching profile just 
slightly slower that ER-Tracker. The data clearly highlight how the cationic complexes exhibit 
better photostability than their neutral analogues. The same general trend was also observed from 
photobleaching experiments in cuvettes using 10-5 M aqueous solutions (0.2% DMSO), excited 
using a Pen-Ray Mercury Lamp source at 365 nm (see SI for experimental details). 
 
Conclusions 
This work reports the synthesis of iridium tetrazolato complexes and their potential use as imaging 
agents in live cells. A library of neutral complexes displaying chemical variations at the 
cyclometalating phenylpyridine and tetrazolato ligands was synthesised. Furthermore, methylation 
of these species allowed facile access to the corresponding cationic complexes, so that a SAR for 
cellular internalisation, localisation, and cytotoxicity could be more systematically investigated. The 
photophysical properties of these species revealed typical phosphorescent emission from excited 
states of charge transfer nature, as a mixture of 3MLCT and 3LLCT. The emission of the complexes 
was found to be in general solvatochromic, with a red-shift occurring upon increase of medium 
polarity. Quantification of cellular incubation via ICP-MS revealed great variability, with trends 
that cannot be simply correlated to the degree of lipophilicity and charge of the complexes. These 
results suggest potentially different mechanisms of uptake, and a comparison of the emission 
intensity from cells incubated at 37 and 4 °C reveals these are predominantly energy mediated. The 
majority of the complexes were internalised into cells and detection was possible via either one-
photon or two-photon imaging modalities. The neutral species were predominantly localised within 
the endoplasmic reticulum and to various extents within lipid droplets. On the other hand, the 
cationic species exhibited more specificity for mitochondria. A marked difference between the 
neutral and cationic probes was found in terms of cytotoxicity, which was restricted mainly to the 
charged complexes during long term experiments. The higher cytotoxicity of the cationic 
complexes does not seem to be exclusively linked to the amount of complex internalised within the 
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cells, and it is potentially highly dependent also on the localisation. This study has therefore 
highlighted that neutral iridium tetrazolato complexes are suitable building blocks for the design of 
markers for cellular imaging on long timescales, and more specifically for the imaging of ER and 
lipid droplets. However, specific protocols for imaging modalities (e.g. resting time between 
consecutive excitation regimes) are essential to avoid photocytotoxicity. On the other hand, cationic 
iridium tetrazolato complexes are good candidates for the design of mitochondrial markers. 
However, careful considerations must be taken for longer time experiments, as these cationic 





Unless otherwise stated, all reagents and solvents were purchased from Sigma Aldrich or Alfa 
Aesar and used as received without further purification. The species HTzQn,[81] HTziQn,[81] 
[Ir(ppy)2(µ-Cl)]2,[82] [Ir(F2ppy)2(µ-Cl)]2[82] and [Ir(ppy)2(TzPyBr)][11] were prepared according to 
previously published procedures. Detailed synthetic procedures for the iridium complexes and 
corresponding ligands described in this work are reported in the SI. 
Nuclear magnetic resonance spectra were recorded using a Bruker Avance 400 spectrometer (400 
MHz for 1H NMR; 100 MHz for 13C NMR) at 300 K. All NMR spectra were calibrated to residual 
solvent signals. Infrared spectra were recorded using an attenuated total reflectance Perkin Elmer 
Spectrum 100 FT-IR with a diamond stage. IR spectra were recorded from 4000–650 cm-1. The 
intensity of the band is reported as strong (s), medium (m), or weak (w), with broad (br) bands also 
specified. Melting points were determined using a BI Barnsted Electrotermal 9100 apparatus. 
Elemental analyses were carried out on bulk samples using a Thermo Finning EA 1112 Series 
Flash; the presence of solvents in the bulk samples was further confirmed by 1H NMR. 
 
X-ray crystallography 
Crystallographic data for the structure were collected at 100(2) K on an Oxford Diffraction Gemini 
diffractometer with Mo Kα or Cu Kα radiation.  Following absorption corrections and solution by 
direct methods, the structures were refined against F2 with full-matrix least-squares using the 
program SHELXL-2014.[83] All hydrogen atoms were added at calculated positions and refined by 
use of riding models with isotropic displacement parameters based on those of the parent atoms. 
Anisotropic displacement parameters were employed throughout for the non-hydrogen atoms. 
Structure refinement data are reported in the SI. 
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Photophysical measurements 
Absorption spectra were recorded at room temperature using a Cary 4000 UV/Vis spectrometer. 
Uncorrected steady state emission and excitation spectra were recorded on an Edinburgh FLSP980-
S2S2-stm spectrometer equipped with: i) a temperature-monitored cuvette holder; ii) 450 W Xenon 
arc lamp; iii) double excitation and emission monochromators; iv) a Peltier cooled Hamamatsu 
R928P photomultiplier tube (spectral range 200-870 nm). Emission and excitation spectra were 
corrected for source intensity (lamp and grating) and emission spectral response (detector and 
grating) by a calibration curve supplied with the instrument. According to the approach described 
by Demas and Crosby,[84] luminescence quantum yields (Φem) were measured in optically dilute 
solutions (O.D. < 0.1 at excitation wavelength) obtained from absorption spectra on a wavelength 




where A is the absorbance at the excitation wavelength (λ), I is the intensity of the excitation light at 
the excitation wavelength (λ), n is the refractive index of the solvent, D is the integrated intensity of 
the luminescence and Φ is the quantum yield. The subscripts r and x refer to the reference and the 
sample, respectively. The quantum yield determinations were performed at identical excitation 
wavelength for the sample and the reference, therefore cancelling the I(λr)/I(λx) term in the 
equation. The quantum yields of complexes were measured against an aqueous solution of 
[Ru(bipy)3]Cl2 (bipy = 2,2’-bipyridine; Φr = 0.028).[85] Emission lifetimes (τ) were determined 
with the time correlated single photon counting technique (TCSPC) with the same Edinburgh 
FLSP980-S2S2-stm spectrometer using either a pulsed picosecond LED (EPLED/EPL 377 nm, 
FHWM < 800 ps). The goodness of fit was assessed by minimising the reduced χ2 function and by 
visual inspection of the weighted residuals. The solvents used for the preparation of the solutions 
for the photophysical investigations were of LR grade and the water was deionised. Degassing of 
the dichlorometane solutions was performed using the freeze-pump-thaw method. Experimental 
uncertainties are estimated to be ±8% for lifetime determinations, ±20% for quantum yields, ±2 nm 
and ±5 nm for absorption and emission peaks, respectively. 
 
TD-DFT  






































Prior to these calculations, the structures were relaxed at the B3LYP level of theory. [87,88] The Ir 
atoms were treated with the Stuttgart-Dresden effective core potential,[89] the Pople 6-311G** basis 
set was used for all the other atoms, and the effect of the solvent was mimicked with the PCM 
solvation model,[90] with parameters adequate for dichloromethane. The low-lying singlet–singlet 
excitation energies were calculated at the same level of theory, and the spectra were reproduced as 
the superposition of Gaussian functions with heights proportional to calculated intensities and a 
variance of 11 nm.  
 
Cell culture 
H9c2 rat cardiomyoblast cells were maintained in high-glucose (4500 mg/L) DMEM medium 
(Sigma-Aldrich, USA) containing 10% fetal bovine serum (FBS; In Vitro Technologies, USA) and 
2 mM L-glutamine (Sigma-Aldrich, USA) at 37 ºC and 5% CO2. The H9c2 cells were cultured in 
75 mm2 flasks. Cells that had been passaged  for no more than 18 times, were used for experiments. 
For ICP-MS, H9c2 cells were seeded at 2.7×104 cells/mL and grown in T25 flasks for 72 h, when 
100% confluence was reached. For live cell imaging and MTS assay, the H9c2 cells were seeded at 
1 x 105 cells/mL and cultured overnight in either ibidi µ-slide 8 wells in a final volume of 250 µL or 
96-well microtiter plate in a final volume of 200 µL. 
 
ICP-MS 
The H9c2 cells were incubated with the iridium complexes at 20 µM (prepared in DMEM full 
culture media with 0.2% DMSO) for 30 minutes at 37 ºC and 5% CO2 . The cells were washed three 
times with phosphate buffered saline (PBS), and then detached with TripLE Express reagent 
(Gibco, USA) for 2 minutes. The cells were then washed from T25 flasks with 3 mL of DMEM full 
culture medium, and pelleted by centrifugation at 400 rpm for 10 minutes. The medium was 
removed and the cells were resuspended in 2 mL of PBS for cells counts. The remaining cells were 
centrifuged at 1000 rpm for 10 minutes, the medium was then removed leaving behind the stained 
cell pellets, which were desiccated for 3.5 h at 95 °C. The pellets were reconstituted in 36% HCl 
(400 µL) and left at 95 °C until dry in order to digest organic material. The dry samples were then 
reconstituted in 2% HCl (2.5 mL) and sonicated for 10 minutes before filtering (pore diameter of 
0.2 µm). The total iridium determination was performed with an Agilent 8900x triple quad ICP-MS 
(Agilent Technologies, USA), using He gas (4 mL/min).  
 
Cell staining 
H9c2 cells were incubated with the iridium complexes at 20 µM in DMEM full culture medium 
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with 0.2% DMSO for 30 minutes at either 37 ºC or 4 ºC. The cells were washed twice with PBS, 
before imaging in DMEM. For co-staining experiments, the cells were then incubated with ER-
Tracker™ Red, MitoTracker® Red CMXRos, or BODIPY® 500/510 C1,C12 (Life Technologies 
Australia Pty Ltd, Australia), following manufacturer’s instructions.  
 
Confocal micoscopy 
Single photon live cell imaging was performed using a Nikon A1+ confocal microscope (Nikon, 
Japan) with a OKOLab Microscope Incubator (Okolab USA Inc., USA). The iridium complexes 
were excited at 403 nm and the emission was collected in the 525-644 nm region; ER-Tracker and 
MitoTracker were excited at 561 nm and the emission was collected in the region 570-620 nm. 
BODIPY 500/510 was excited at 488 nm and the emission was collected in the region 500-550 nm. 
Image analysis including, co-localisation and emission intensity was measured using NIS elements 
V4.50 software (Nikon, Japan). The final preparation of the images was conducted with Adobe 
Photoshop CC (Adobe Systems Inc., USA). Two-photon microscopy imaging was performed using 
a Zeiss LSM710 META NLO inverted microscope supplemented with a two-photon Mai-Tai®, 
tunable Ti:Sapphire femtosecond pulse laser (710–920 nm, Spectra-Physics). The emission from the 
iridium complexes was detected using the following settings: two-photon excitation wavelength at 
830 nm, beam splitter MBS 690+, emission interval 520–650 nm. The images were acquired using 
a Plan-APOCHROMAT 63X/ NA1.4 oil immersion objective. The final preparation of the images 
was conducted with Adobe Photoshop CC (Adobe Systems Inc., USA). 
 
MTS cell viability assay 
The cellular NADPH-dependent redox activity was measured using CellTiter 96® AQueous Non-
Radioactive Cell Proliferation Assay (MTS), according to the manufacturer’s instruction (Promega, 
USA). The H9c2 cells were stained with the iridium complexes at either 20 µM or 40 µM in 
DMEM full cell culture medium with 0.2% DMSO, and held at 37 °C and 5% CO2 for 4 or 24 
hours. As a control, H9c2 cells were incubated for the same length of time in DMEM with 0.2% 
DMSO. Following addition of MTS, the cells incubation  for a further 2 hours at 37 ºC and 5% 
CO2. The absorbance of the formazan dye was measured by EnVision multi-label plate reader 
(PerkinElmer, Beaconsfield, UK) at 490 nm. The data are reported as the mean ± SEM of three 
biological replicates for each group. 
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A glowing family in cell. Neutral iridium tetrazolato complexes provide exceptional building block 
for the design of molecular probes for the endoplasmic reticulum in live cells, while methylation 
causes the complexes to shift interaction to the mitochondria and exhibit enhanced cytotoxicity. 
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